Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line of Therapy Who Are Lenalidomide Refractory.
NCT05581875 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line of Therapy Who Are Lenalidomide Refractory.
- Lead sponsor
- Hellenic Society of Hematology
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- October 20, 2022
- Completion date
- October 31, 2026
- Enrollment
- 48 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
blood protein disorders, corneal disease, gammopathy, monoclonal, haematologic disease, multiple myeloma, multiple myeloma in relapse, neoplasms, neoplasms, plasma cell, paraproteinemias